FDA warned Zhejiang Easyclean Daily Chemical that its OTC drugs lacked required testing and manufacturing controls.
What happened
FDA reviewed records the company submitted after FDA's March 11, 2024 request for records and later correspondence; there was no inspection. The records showed no finished-product testing of active ingredient identity or strength before release, inadequate stability data and expiration dates, incomplete batch records, and no process validation for OTC drugs shipped to the U.S. market.
What FDA found
Did not test each finished drug batch for identity and strength of active ingredients before release.
21 CFR 211.165(a)Failed to establish an adequate stability program; it had only three months of accelerated data, no long-term data, and no testing of the active ingredient to support expiration dates.
21 CFR 211.166(a)Batch production and control records lacked formulation, equipment identity, step durations, and names of people performing steps.
21 CFR 211.188Had no written production and process control procedures and had performed no validation of its drug manufacturing processes.
21 CFR 211.100(a)
What FDA wants
FDA tells the company to respond in writing within 15 working days with corrective action plans, finished-product testing plans, a stability program, complete batch records, and validation plans; it also recommends a qualified CGMP consultant.
Who should pay attention
- U.S. distributors and retailers selling imported OTC drugs
- brands using this contract manufacturer for private-label drugs
- quality teams auditing overseas OTC drug suppliers
This is a summary. Read the original letter on fda.gov.